` DMP (Dermapharm Holding SE) vs DAX Index Comparison - Alpha Spread

DMP
vs
D
DAX Index

Over the past 12 months, DMP has underperformed DAX Index, delivering a return of -4% compared to the DAX Index's +10% growth.

Stocks Performance
DMP vs DAX Index

Loading
DMP
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
DMP vs DAX Index

Loading
DMP
DAX Index
Difference
www.alphaspread.com

Performance By Year
DMP vs DAX Index

Loading
DMP
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Dermapharm Holding SE vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Dermapharm Holding SE
Glance View

Market Cap
3.9B EUR
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Dermapharm Holding SE stands as a noteworthy player, crafting a narrative of strategic growth and innovation. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm presents itself as a vertically integrated pharmaceutical company whose operations stretch from development and production to marketing and distribution. This integration allows them to maintain control over their value chain, ensuring efficiency and quality across diverse product lines. Dermapharm's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices, fortified through keenly orchestrated acquisitions that enhance their market presence and product offerings. Such strategic steps enable Dermapharm to leverage established brands while venturing into new sectors, reinforcing its reputation as a dynamic force in the pharmaceutical landscape. Dermapharm primarily generates revenue by capitalizing on dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements. By addressing a broad spectrum of chronic and everyday health conditions, they serve both niche and mass-market demands across Europe. Dermapharm’s distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors. Additionally, Dermapharm collaborates with partners to penetrate new geographical markets, thereby diversifying their revenue streams. Such initiatives underscore the company's agility and strategic foresight, ensuring sustained growth in a competitive industry.

DMP Intrinsic Value
51.05 EUR
Undervaluation 28%
Intrinsic Value
Price
Back to Top